A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors

被引：0
|
作者：
Cho, Byoung Chul
Lu, Shun
Lee, Myung Ah
Song, Zhengbo
Park, John
Lim, Sun Min
Li, Ziming
Zhao, Jun
Richardson, Gary
Zhang, Yanqiao
Zhang, Jun
Liu, Anwen
Chen, Cheng
Wang, Jia
Lu, Jingtao
Rui, Haopeng
Chen, Qian
Wang, Hui
Zhang, Jing
Chen, Zhi Jian
Mok, Tony
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT117
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
    Wang, Judy
    Martin-Romano, Patricia
    Cassier, Philippe
    Johnson, Melissa
    Haura, Eric
    Lenox, Laurie
    Guo, Yue
    Bandyopadhyay, Nibedita
    Russell, Michael
    Shearin, Elizabeth
    Lauring, Josh
    Dahan, Laetitia
    ONCOLOGIST, 2022, 27 (07): : 536 - +
  • [22] Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.
    Zhao, Jun
    Fang, Jian
    Yu, Yan
    Chu, Qian
    Li, Xiaoyan
    Chen, Jiayan
    Liu, Zhe
    Zhang, Li
    Wu, Lin
    Zhuang, Wu
    Li, XingYa
    Zhao, Yanqiu
    Xing, Ligang
    Liu, Lian
    Bai, Chunmei
    Dong, Xiaorong
    Song, Qibin
    Pan, Pinghua
    Fang, Xuefeng
    Wang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] NURSING EXPERIENCE WITH PATIENTS RECEIVING SOTORASIB FOR KRAS G12C-MUTATED SOLID TUMORS: FOLLOW-UP FROM THE PHASE 1/2 CODEBREAK 100 STUDY
    Dozier, Askia
    Fitzpatrick, Victoria
    Liu, Dazhi
    Hull, Jennifer
    Varrieur, Tracy
    McGuire, Lauren
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : 22 - 23
  • [24] Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101)
    Fakih, M.
    Durm, G.
    Govindan, R.
    Falchook, G.
    Soman, N.
    Henary, H.
    Hong, D. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S28
  • [25] First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.
    Liu, Rongrui
    Qu, Xiujuan
    Yang, Nong
    Chai, Xiaoli
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
    Heymach, J.
    Kotecki, N.
    Prenen, H.
    Alonso, G.
    Lindsay, C. R.
    Barve, M.
    Thamer, C.
    Eigenbrod-Giese, S.
    Marotti, M. A.
    Van Lancker, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S468 - S468
  • [27] Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study
    Kuboki, Yasutoshi
    Murciano-Goroff, Yonina R.
    Yaeger, Rona
    Cassier, Philippe Alexandre
    Heist, Rebecca Suk
    Fujiwara, Yutaka
    Deming, Dustin A.
    Ammakkanavar, Natraj
    Patnaik, Amita
    Shimizu, Toshio
    Call, Justin
    Han, Sae-Won
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Balar, Arjun Vasant
    Koyama, Takafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 94 - 94
  • [28] KontRASt-01: A Phase Ib/II Dose Escalation Study of JDQ443 in Patients with advanced KRAS G12C mutated solid Tumors
    Schuler, M.
    Tan, D. S.
    Shimizu, T.
    Solomon, B.
    Heist, R. S.
    de Miguel, M.
    Gazzah, A.
    Wermke, M.
    Dooms, C.
    Loong, H. H.
    Steeghs, N.
    Felip, E.
    Steuer, C. E.
    Van Cutsem, E.
    Soo, R. A.
    Jaeger, A.
    Kim, J.
    Xu, K.
    Cui, X.
    Burks, H.
    Farago, A. F.
    Cassier, P. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 29 - 29
  • [29] Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations
    Abdul-Quddus Kehinde Oyedele
    Abdeen Tunde Ogunlana
    Ibrahim Damilare Boyenle
    Najahtulahi Opeyemi Ibrahim
    Ibrahim Olajide Gbadebo
    Nurudeen Abiodun Owolabi
    Ashiru Mojeed Ayoola
    Ann Christopher Francis
    Olajumoke Habeebah Eyinade
    Temitope Isaac Adelusi
    Molecular Diversity, 2023, 27 : 1795 - 1807
  • [30] Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations
    Oyedele, Abdul-Quddus Kehinde
    Ogunlana, Abdeen Tunde
    Boyenle, Ibrahim Damilare
    Ibrahim, Najahtulahi Opeyemi
    Gbadebo, Ibrahim Olajide
    Owolabi, Nurudeen Abiodun
    Ayoola, Ashiru Mojeed
    Francis, Ann Christopher
    Eyinade, Olajumoke Habeebah
    Adelusi, Temitope Isaac
    MOLECULAR DIVERSITY, 2023, 27 (04) : 1795 - 1807
12345